What Happened?
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Outpatient & Specialty Care company agilon health (NYSE:AGL) fell 3.2%. Is now the time to buy agilon health? Access our full analysis report here, it’s free.
- Outpatient & Specialty Care company LifeStance Health Group (NASDAQ:LFST) fell 4%. Is now the time to buy LifeStance Health Group? Access our full analysis report here, it’s free.
- Senior Health, Home Health & Hospice company The Pennant Group (NASDAQ:PNTG) fell 3.4%. Is now the time to buy The Pennant Group? Access our full analysis report here, it’s free.
- Branded Pharmaceuticals company Corcept (NASDAQ:CORT) fell 3%. Is now the time to buy Corcept? Access our full analysis report here, it’s free.
- Generic Pharmaceuticals company Amphastar Pharmaceuticals (NASDAQ:AMPH) fell 5.8%. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it’s free.
Zooming In On Amphastar Pharmaceuticals (AMPH)
Amphastar Pharmaceuticals’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 7 days ago when the stock dropped 3% on the news that the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions.
Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses.
Amphastar Pharmaceuticals is down 43.4% since the beginning of the year, and at $20.58 per share, it is trading 61.5% below its 52-week high of $53.40 from November 2024. Investors who bought $1,000 worth of Amphastar Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $983.04.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.